197 related articles for article (PubMed ID: 24786491)
1. Regulation of Epstein-Barr virus reactivation from latency.
Murata T
Microbiol Immunol; 2014 Jun; 58(6):307-17. PubMed ID: 24786491
[TBL] [Abstract][Full Text] [Related]
2. Switching of EBV cycles between latent and lytic states.
Murata T; Tsurumi T
Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
[TBL] [Abstract][Full Text] [Related]
4. Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.
Murata T; Narita Y; Sugimoto A; Kawashima D; Kanda T; Tsurumi T
J Virol; 2013 Sep; 87(18):10148-62. PubMed ID: 23843637
[TBL] [Abstract][Full Text] [Related]
5. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
Robinson AR; Kwek SS; Kenney SC
PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
[TBL] [Abstract][Full Text] [Related]
7. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
8. Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.
Imai K; Kamio N; Cueno ME; Saito Y; Inoue H; Saito I; Ochiai K
FEBS J; 2014 May; 281(9):2148-58. PubMed ID: 24588869
[TBL] [Abstract][Full Text] [Related]
9. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
Woellmer A; Arteaga-Salas JM; Hammerschmidt W
PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
[TBL] [Abstract][Full Text] [Related]
10. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein.
Murata T; Sato Y; Nakayama S; Kudoh A; Iwahori S; Isomura H; Tajima M; Hishiki T; Ohshima T; Hijikata M; Shimotohno K; Tsurumi T
J Biol Chem; 2009 Mar; 284(12):8033-41. PubMed ID: 19164291
[TBL] [Abstract][Full Text] [Related]
11. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.
Hergenhahn M; Soto U; Weninger A; Polack A; Hsu CH; Cheng AL; Rösl F
Mol Carcinog; 2002 Mar; 33(3):137-45. PubMed ID: 11870879
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Jun dimerization protein 2 (JDP2) in the maintenance of Epstein-Barr virus latency.
Murata T; Noda C; Saito S; Kawashima D; Sugimoto A; Isomura H; Kanda T; Yokoyama KK; Tsurumi T
J Biol Chem; 2011 Jun; 286(25):22007-16. PubMed ID: 21525011
[TBL] [Abstract][Full Text] [Related]
13. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
[TBL] [Abstract][Full Text] [Related]
14. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
[TBL] [Abstract][Full Text] [Related]
15. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
[TBL] [Abstract][Full Text] [Related]
16. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells.
Daibata M; Speck SH; Mulder C; Sairenji T
Virology; 1994 Feb; 198(2):446-54. PubMed ID: 8291228
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latency.
Murata T; Tsurumi T
Front Genet; 2013; 4():53. PubMed ID: 23577022
[TBL] [Abstract][Full Text] [Related]
19. A role for the nucleosome assembly proteins TAF-Iβ and NAP1 in the activation of BZLF1 expression and Epstein-Barr virus reactivation.
Mansouri S; Wang S; Frappier L
PLoS One; 2013; 8(5):e63802. PubMed ID: 23691099
[TBL] [Abstract][Full Text] [Related]
20. Histone acetylation and reactivation of Epstein-Barr virus from latency.
Jenkins PJ; Binné UK; Farrell PJ
J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
